Swanbridge Capital
  • Home
  • Our Story
  • Strategy
  • Portfolio
  • Team
  • News & Events
  • Contact
Select Page

DegenRx secures funding for Alzheimer’s disease gene therapy

by stefan | Dec 21, 2018 | Blog, Geen categorie

TILBURG, The Netherlands, 20 December 2018 – DegenRx B.V. a biopharmaceutical company developing novel therapeutic solutions to treat neurodegenerative diseases, announced today that they have secured financing for their antibody-based gene therapy program for the...

Recent Posts

  • Allero Therapeutics and Abbreos join forces to clinically develop COVID-19 program
  • Swanbridge Capital invests in Immagene
  • Curie Capital invests in Allero Therapeutics
  • Allero Therapeutics secures seed investment from Swanbridge Capital
  • DegenRx secures funding for Alzheimer’s disease gene therapy

Recent Comments

    Archives

    • November 2020
    • September 2020
    • October 2019
    • April 2019
    • December 2018
    • July 2018
    • December 2017
    • October 2017
    • December 2016

    Categories

    • Blog
    • Geen categorie

    Meta

    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.org
    • Facebook
    • Twitter
    • Google
    • RSS

    Designed by Elegant Themes | Powered by WordPress